The development of oedema in patients with COPD is associated with stimulation of the renin-angiotensin-aldosterone axis and increased ADH release.68 The raised aldosterone levels may contribute to sodium retention and the increased ADH levels to hyponatraemia. However, rather than being the cause of the oedema in hypoxaemic COPD, these changes might reflect other aspects of the disease such as a further reduction in renal blood flow, altered intrarenal haemodynamics, the stress of the disease, or even the effects of treatment with drugs such as diuretics.
disease (COPD) develop cor pulmonale with sodium and water retention. The sodium retention has been explained as a result of increased plasma levels of aldosterone. If this was true angiotensin converting enzyme (ACE) inhibition would be expected to lower plasma levels of aldosterone and improve the renal excretion of sodium. Methods -Six patients with stable hypoxaemic COPD (Pao2 <80 kPa) and a history of an oedematous exacerbation received an intravenous hypertonic saline load (6 ml/kg body weight of 2 7% saline over one hour) before and while taking 4mg/day perindopril, an ACE inhibitor, for one month. Aldosterone, antidiuretic hormone (ADH), plasma and urine electrolyte levels, osmolality, and volume were measured over four hours. The repeatability of the saline load test was assessed in six patients with a similar severity of hypoxaemic COPD. For comparison the saline load test was also performed in six patients with mild COPD. Results -The hypertonic saline load test results were repeatable. Perindopril reduced the mean (SD) plasma level of aldosterone from 142 (88) pg/ml to 54 (24) pg/ ml at 0 minutes before the saline infusion, and from 64 (35) pg/ml to 30 (17) pg/nml after the infusion without improving the urinary volume or sodium excretion. Before starting treatment with perindopril 43*7 (6.9) mmol (20%) of the sodium load was excreted compared with (7.9) mmol (22% of load) when taking perindopril. Patients The development of oedema in patients with COPD is associated with stimulation of the renin-angiotensin-aldosterone axis and increased ADH release.68 The raised aldosterone levels may contribute to sodium retention and the increased ADH levels to hyponatraemia. However, rather than being the cause of the oedema in hypoxaemic COPD, these changes might reflect other aspects of the disease such as a further reduction in renal blood flow, altered intrarenal haemodynamics, the stress of the disease, or even the effects of treatment with drugs such as diuretics.
If the activation of the renin-angiotensinaldosterone system with increased levels of angiotensin II and aldosterone was the major determinant of the sodium retention seen in hypoxaemic COPD, its blockade by an angiotensin converting enzyme (ACE) inhibitor should improve the ability of these oedematous patients to excrete a hypertonic saline load. perindopril(n -6) perindopril(n= 6)
Methods
Urinary volume (ml) Blood samples for measurement of urea, electrolytes (Technicon SMAC analyser), and osmolality (Advance osmometer 2WII) were collected into serum tubes, and plasma samples for ADH and aldosterone assay into tubes containing ethylenediaminetetra-acetate (EDTA). The EDTA tubes were centrifuged immediately and the plasma removed and frozen at -20°C until assayed. Samples were taken at the following times: -30, 0, 60, 120, 180, and 240 minutes after the saline infusion.
Between 0 and 60 minutes the subjects received a 2-7% (3N) saline (450 mmol/l) intravenous infusion at a constant rate of 0-1 ml/ kg/min. Blood pressure and oxygen saturation were recorded at each time point. After four hours arterial blood gases were taken, the patients emptied their bladders, urine volume was noted, and urine excretion of sodium and creatinine and urine osmolality were measured.
Creatinine plasma levels of aldosterone found in patients with stable oedematous COPD are not the main cause of their impaired ability to excrete shows the reproducibility of the pro-a saline load. These results also suggest that 'ith the exception of aldosterone levels long term ACE inhibition may be ineffective linutes the differences in the two read-in the chronic management of oedematous cor e not significant. Patient characteristics pulmonale. nilar in both control and perindopril
In the acute situation, however, particularly abjects (mean FEVy 1.1 (04)1 and in decompensated oedematous exacerbations 1 I respectively, and mean PaO2 7 8 (0 6) where aldosterone levels are high,5 ACE inl 7-1 (0 9) kPa respectively). In the hibition might prove therapeutically useful. In with severely hypoxaemic COPD an acute study a single 25 mg dose of captopril :ts of hypertonic saline loading were given to a comparable group of patients with )rily reproducible in terms of sodium hypoxaemic COPD receiving a similar hyper--r excretion, serum sodium levels and tonic saline load did marginally improve UbIlllUldlILY L;I1dI1gUS3 U11W Plabllld UIlW<bfLC-VlC levels at the beginning of the study challenges.
Before taking perindopril the patients with oedematous hypoxaemic COPD had levels of aldosterone significantly higher than the control group at -30 and 0 minutes. However, these results were within the quoted normal ranges. Aldosterone levels fell appropriately during the intravenous hypertonic saline load (fig 1) .
No adverse reactions to perindopril were reported. The drug produced a significant lowering of aldosterone (p<0 05) (fig 1) at all time points with the exception of 240 minutes but, despite this, there was no improvement in sodium excretion (table 2) . Likewise the volume of urine excreted did not increase on perindopril. The levels of ADH were insignificantly lower on the perindopril day ( fig  2) . The levels of both these hormones whilst on perindopril were similar to values obtained in control patients with mild COPD (FEV, [1] [2] [3] [4] [5] [6] [7] (0 6) l and Pao2 9 7 (0 6) kPa) (figs 1 and 2). These controls excreted significantly greater amounts of sodium and water (p<005) (table  2) . Likewise, perindopril did not alter the fractional sodium reabsorption, serum sodium levels, urinary or plasma osmolality, or glomerular filtration rate. sodium excretion.9 The fact that the patients were rendered normoxic by supplemental oxygen throughout the experiment might also account for the differences from our study.
However, such acute studies should not be compared with chronic treatment where the many limbs of these complex homeostatic reflexes will compensate for the alteration in any one part of the regulatory mechanism.
The lack of effect of ACE inhibition in improving sodium excretion in patients with oedematous hypoxaemic COPD is reminiscent of the lack of effect of captopril in nephrotic syndrome, a condition which is also associated with sodium and water retention and a stimulation of the renin-angiotensin-aldosterone system.'2 It is probable that the increase in aldosterone levels is more an effect of the disease process than the cause.
The small increases in urine volume and sodium excretion seen in patients on perindopril were within the levels of test reproducibility. It is possible that in a much larger group the small improvement in sodium excretion might have reached significance. Such a small increase in excretion would, however, be too small to be important. It comprises only a very small part of the impairment in sodium and water excretion seen in these patients with cor pulmonale.
The failure of ACE inhibition to increase sodium excretion is not due to a concomitant fall in atrial natriuretic peptide. Levels This study did not assess the effects of ACE inhibition on the frequency of oedematous decompensations, nor did it measure improvement in well being, dyspnoea, or exercise tolerance. Such improvements have been seen with perindopril in congestive cardiac failure. '7 It is possible, however, for these benefits to occur without improvement in natriuresis and diuresis. '5 In conclusion, in oedematous hypoxaemic patients with COPD the ACE inhibitor perindopril lowered the levels of plasma aldosterone without improving their impaired ability to excrete a hypertonic saline load. This suggests that the chronic increase in aldosterone levels seen in patients with oedematous hypoxaemic COPD is not the prime cause ofthe impaired ability to excrete a sodium load. The increased levels of aldosterone might be an effect of hypoxaemic COPD or the treatment -for example, diuretics. However, this study does not rule out the possibility that increased levels of aldosterone may be important during acute oedematous exacerbations and that, under these acute situations, ACE inhibition might have a beneficial therapeutic effect.
